Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Lung cancer and imaging / / edited by Ayman El-Baz, Jasjit S. Suri
| Lung cancer and imaging / / edited by Ayman El-Baz, Jasjit S. Suri |
| Pubbl/distr/stampa | Bristol [England] (Temple Circus, Temple Way, Bristol BS1 6HG, UK) : , : IOP Publishing, , [2020] |
| Descrizione fisica | 1 online resource (various pagings) : illustrations (some color) |
| Disciplina | 616.99/424075 |
| Collana |
IOP ebooks. [2020 collection]
IPEM-IOP series in physics and engineering in medicine and biology |
| Soggetto topico |
Lungs - Cancer - Imaging
Lung Neoplasms - diagnostic imaging Radiography Diagnostic Imaging - methods Medical imaging MEDICAL / Allied Health Services / Imaging Technologies |
| ISBN |
0-7503-2539-9
0-7503-2540-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
1. Early diagnosis system for lung nodules based on the integration of a higher-order MGRF appearance feature model and 3D-CNN -- 1.1. Introduction -- 1.2. Methods -- 1.3. Experimental results -- 1.4. Conclusion
2. Capsule networks for lung cancer screening -- 2.1. Introduction -- 2.2. Capsule network -- 2.3. Fast capsule network -- 2.4. Dataset -- 2.5. Experiments -- 2.6. Results and discussion -- 2.7. Conclusions 3. Quantitative malignancy recognition of lung cancer using non-invasive image modalities -- 3.1. Introduction -- 3.2. Materials and methods -- 3.3. Conclusion 4. Epidemiology of lung cancer -- 4.1. Descriptive epidemiology of lung cancer -- 4.2. Risk factors of lung cancer -- 4.3. Lung cancer in never-smokers -- 4.4. Screening -- 4.5. Conclusion 5. Use of biomarkers in lung cancer diagnosis, prognosis, and treatment -- 5.1. Introduction -- 5.2. Histological subtypes and respective personalized medicine -- 5.3. Available screening assays to detect molecular alterations and genetic rearrangements -- 5.4. Molecular methods used to detect mutations -- 5.5. Genomic markers -- 5.6. Proteomic markers -- 5.7. Metabolic markers -- 5.8. Immunotherapy markers -- 5.9. The emerging role of microRNAs -- 5.10. Clinical trials with targetable oncogenic drivers -- 5.11. Conclusion 6. Radiomics and lung cancer : promising news for early detection of nodules -- 6.1. Introduction -- 6.2. Interpretation of small lung nodules -- 6.3. Computer-aided detection/diagnosis (CAD) -- 6.4. Radiomics -- 6.5. Conclusion 7. Photodynamic diagnosis and treatment of lung cancer -- 7.1. Introduction -- 7.2. Cancer -- 7.3. Photodynamic diagnosis -- 7.4. Photodynamic therapy -- 7.5. Conclusion 8. Cold atmospheric plasma and iron oxide based magnetic nanoparticles for synergetic lung cancer therapy -- 8.1. Introduction -- 8.2. Therapeutic effect of cold atmospheric plasma in lung cancer -- 8.3. The therapeutic effect of magnetic iron oxide nanoparticles in lung cancer -- 8.4. Synergistic therapeutic effects of cold atmospheric plasma and magnetic iron oxide nanoparticles in lung cancer -- 8.5. The synergistic therapeutic effect of cold atmospheric plasma and drug-loaded magnetic nanoparticles in lung cancer -- 8.6. Conclusions 9. Exploiting exhaled aerosol fingerprints to detect lung cancers and obstructive respiratory diseases -- 9.1. Introduction -- 9.2. Methods and materials -- 9.3. Results -- 9.4. Discussion -- 9.5. Conclusion 10. A study of ground-glass opacity (GGO) nodules in the automated detection of lung cancer -- 10.1. Introduction -- 10.2. Ground-glass opacity (GGO) nodules -- 10.3. Computer-aided detection of GGO nodules -- 10.4. Different ways to handle GGOs in automated detection -- 10.5. Conclusion 11. Electromagnetic imaging and lung ablation -- 11.1. Introduction -- 11.2. Electrical impedance tomography -- 11.3. Magnetic induction tomography -- 11.4. Microwave imaging -- 11.5. Lung ablation -- 11.6. Current trends and future perspectives -- 11.7. Conclusion. |
| Record Nr. | UNISA-996344046903316 |
| Bristol [England] (Temple Circus, Temple Way, Bristol BS1 6HG, UK) : , : IOP Publishing, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Lung cancer screening : practical aspects for primary care / / edited by Janelle V. Baptiste, Richard M. Schwartzstein, Carey C. Thomson
| Lung cancer screening : practical aspects for primary care / / edited by Janelle V. Baptiste, Richard M. Schwartzstein, Carey C. Thomson |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (131 pages) |
| Disciplina | 262 |
| Soggetto topico |
Lungs - Cancer - Diagnosis
Lung Neoplasms - diagnostic imaging Lung Neoplasms - diagnosis Early Detection of Cancer Diagnostic Screening Programs |
| ISBN | 3-031-10662-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Introduction -- Contents -- Chapter 1: Epidemiology of Lung Cancer and Risk Factors -- 1.1 Epidemiology of Lung Cancer -- 1.1.1 Incidence -- 1.1.2 Mortality -- 1.1.3 Stage at Presentation -- 1.1.4 Histological Subtypes -- 1.2 Lung Cancer Risk Factors -- 1.2.1 Demographic Factors -- 1.2.2 Smoking -- 1.2.3 Passive Smoking -- 1.2.4 E-Cigarettes -- 1.2.5 Air Pollution -- 1.2.6 Radon -- 1.2.7 Asbestos -- 1.2.8 Infection -- 1.2.9 Genetics and Family History -- 1.3 Conclusion -- References -- Chapter 2: Health Disparities in Lung Cancer Screening -- 2.1 Overview of Health Disparities in Lung Cancer -- 2.2 The Landscape of Health Disparities in Lung Cancer Screening -- 2.2.1 Disparities Associated with Patient Demographics Including Race and Gender -- 2.2.2 The Role of Social Determinants of Health (SDOH) -- 2.3 Barriers to Lung Cancer Screening -- 2.3.1 Barriers to Lung Cancer Screening That Act at the Health Policy Level -- 2.3.2 Barriers to Lung Cancer Screening That Act at the Health System Level -- 2.3.3 Barriers to Lung Cancer Screening That Act at the Patient Level -- 2.3.4 Barriers to Lung Cancer Screening That Act at the Health Care Provider Level -- 2.4 Overcoming Disparities in Lung Cancer Screening -- References -- Chapter 3: Best Practices in Lung Cancer Screening -- 3.1 Evidence Base for Lung Cancer Screening -- 3.1.1 Introduction -- 3.1.2 Measuring Benefits and Harms of Screening -- 3.1.3 Screening Modalities -- 3.1.3.1 Chest Radiography and Sputum Cytology -- 3.1.3.2 Low-Dose CT Scan -- Observational Studies -- 3.1.3.3 Randomized Clinical Trials -- National Lung Screening Trial -- European Randomized Lung Cancer Screening Trials -- NELSON Trial -- 3.1.4 Patient Selection -- 3.1.5 Evidence of Potential Harms -- 3.1.6 Shared Decision-Making Evidence in Lung Cancer Screening -- 3.1.7 Cost-Effectiveness of Lung Cancer Screening.
3.1.8 Smoking and Lung Cancer Screening -- 3.1.9 Non-lung nodule Findings -- 3.1.10 Evidence Needs -- 3.1.11 Conclusion -- 3.2 Quality Indicators in Lung Cancer Screening Programs -- 3.2.1 Challenges in Developing Quality Metrics in Lung Cancer Screening -- 3.2.2 Expert Consensus in Measuring Program Quality in Lung Cancer Screening -- 3.2.3 National Trends in Screening Rates, Disparities, and Targets -- 3.3 Structure and Governance -- 3.3.1 Steering Committee Governance of CT Lung Screening Programs -- 3.3.2 Program Design -- 3.3.3 Provider Continuing Education -- 3.3.4 Community Outreach -- 3.3.5 Measuring Outcomes -- 3.3.6 Research Oversight -- 3.4 Navigation -- 3.4.1 Introduction -- 3.4.2 Office/Department-Based Navigation -- 3.4.3 Lung Cancer Screening Program Navigation -- 3.4.4 The Benefit of Nursing Navigation in Cancer Screening -- 3.4.5 Navigating Lung Cancer Screening in the Electronic Medical Record -- 3.4.6 Navigation Summary -- References -- Chapter 4: Implementing Lung Cancer Screening in Clinical Practice -- 4.1 Lung Cancer Screening Eligibility Criteria and Confirmation of Eligibility -- 4.1.1 Current Eligibility Criteria for Lung Cancer Screening -- 4.1.2 Determining and Ensuring Eligibility for Lung Cancer Screening (LCS) -- 4.1.3 Suggested Areas of Research -- 4.2 Barriers to Implementing Lung Cancer Screening (LCS) in Clinical Practice -- 4.2.1 Discussing Barriers to Implementation of LCS in Primary Care -- 4.2.2 Lung Cancer Screening Is Complex and Costly -- 4.2.3 External Influences Is a Barrier to Lung Cancer Screening Implementation -- 4.2.4 Future Direction -- 4.3 Integration of Lung Cancer Screening into the Electronic Health Record -- 4.3.1 Areas of Focus for Leveraging the EHR -- 4.3.1.1 Documentation of Lung Cancer Risk Factors -- 4.3.2 EHR Support for Identifying LCS-Eligible Individuals. 4.3.3 Tracking LDCT Findings for Follow-Up -- 4.3.4 Research Gaps -- 4.3.5 Future Directions -- 4.4 Insurance Coverage and Prior Authorization of Lung Cancer Screening -- 4.4.1 Private Insurance Coverage -- 4.4.2 Medicare Coverage -- 4.4.3 Medicaid Coverage -- 4.4.4 Prior Authorization -- References -- Chapter 5: Innovations in Integrating Smoking Cessation and the Shared Decision-Making Discussion into Lung Cancer Screening -- 5.1 Components of a Shared Decision-Making Discussion -- 5.2 Challenges in Shared Decision-Making Decisions: Embracing Uncertainty -- 5.2.1 Biology of the Tumor -- 5.2.2 Concept of False Positives -- 5.2.3 Relative Versus Absolute Risk Reduction -- 5.2.4 Addressing Uncertainty in Lung Cancer Screening -- 5.3 Smoking Cessation -- 5.3.1 Evidence-Based Tobacco Treatment -- 5.3.2 Tobacco Therapy and the Shared Decision -- 5.3.3 Personalized Risk Assessment to Support Quitting -- 5.3.4 Barriers to Quitting -- 5.4 Innovation in Lung Screening and Decision Support Tools -- 5.4.1 What Is Innovation? -- 5.4.2 Current Educational Tools Are Lacking -- 5.4.3 Experiential Learning and Understanding Pulmonary Nodules -- 5.4.4 Measuring the Effectiveness of a Tactile Lung Nodule Tool -- 5.4.5 Innovations for Rural Engagement and Supporting Quitting -- 5.4.6 Virtual Reality: Next Generational Teaching Tool -- References -- Chapter 6: Lung Cancer Screening Results and Tracking -- 6.1 Ordering a LCS CT -- 6.2 Standardized Reporting Protocols and National Registry Requirements -- 6.3 Managing Screening Findings on Lung Cancer Screening CTs -- 6.4 Managing Incidental Findings on Lung Cancer Screening CT -- 6.5 Updates in Lung Cancer Screening Technology -- 6.6 Women and Lung Cancer Screening -- References -- Index. |
| Record Nr. | UNINA-9910616209103321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
